AYJ Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €5.39 |
| 52 Week Low | €2.00 |
| Beta | 1.02 |
| 11 Month Change | -25.87% |
| 3 Month Change | -39.17% |
| 1 Year Change | -61.48% |
| 33 Year Change | -92.98% |
| 5 Year Change | -17.70% |
| Change since IPO | -82.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| AYJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.0% | -0.2% | 0.8% |
| 1Y | -61.5% | -16.9% | 9.1% |
Return vs Industry: AYJ underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: AYJ underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| AYJ volatility | |
|---|---|
| AYJ Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AYJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: AYJ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| AYJ fundamental statistics | |
|---|---|
| Market cap | €327.01m |
| Earnings (TTM) | -€7.42m |
| Revenue (TTM) | €158.54m |
2.1x
P/S Ratio-44.1x
P/E RatioIs AYJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYJ income statement (TTM) | |
|---|---|
| Revenue | €158.54m |
| Cost of Revenue | €163.61m |
| Gross Profit | -€5.08m |
| Other Expenses | €2.34m |
| Earnings | -€7.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | -3.20% |
| Net Profit Margin | -4.68% |
| Debt/Equity Ratio | 79.4% |
How did AYJ perform over the long term?
See historical performance and comparison